This study demonstrated that in the management of blood glucose in hospitalised T2DM patients with hyperglycemia, combination therapy with BBT and empagliflozin achieved considerably higher TIR and lower insulin requirements at an earlier stage than conventional BBT alone. The gene discussed is INS; the disease is Hyperglycemia.